[Case of agrypnia (4 months without sleep) in Morvan's disease. Favorable action of 5-hydroxytryptophan].
D006916:5-Hydroxytryptophan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D002819:Chorea / Q000150:complications* / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004565:Electroconvulsive Therapy; D004569:Electroencephalography; D006212:Hallucinations / Q000209:etiology; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007866:Leg; D008297:Male; D008569:Memory Disorders / Q000209:etiology; D009207:Myoclonus / Q000150:complications* / Q000188:drug therapy; D012892:Sleep Deprivation; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy / Q000209:etiology*; D012894:Sleep Stages; D012895:Sleep, REM; D013997:Time Factors; D014364:Tryptophan / Q000627:therapeutic use; D014851:Wakefulness
D006993:Hypnotics and Sedatives; D006897:Hydroxyindoleacetic Acid; D014364:Tryptophan; D006916:5-Hydroxytryptophan
Sur un cas d'agrypnie (4 mois sans sommeil) au cours d'une maladie de Morvan. Effet favorable du 5-hydroxytryptophane.